We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,512

A summary of major developments in key areas - general counsel update - July 2014
  • Herbert Smith Freehills LLP
  • Australia, European Union, Hong Kong, United Kingdom
  • July 15 2014

Legislation, in the form of a Regulation and Directive, has been published in the Official Journal of the European Union which will substantially

Federal court affirms standing for innovative drug manufacturer
  • Gowling WLG
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the

Substitution allowed? State biosimilars laws are evolving
  • DLA Piper LLP
  • USA
  • September 10 2014

Biosimilar products have not yet reached the US market, but debates on the laws and regulations that will govern them have been raging for some time

  • Shook Hardy & Bacon LLP
  • USA
  • October 2 2014

The U.S. Patent and Trademark Office extends the deadline for applications under its Patents for Humanity Program, "which recognizes patent holders

Computer, diagnostic, and business method patents in the wake of Bilski
  • Calfee Halter & Griswold LLP
  • USA
  • June 29 2010

The Supreme Court's long-awaited Bilski decision is in

Clinical trial agreements: Five key concepts
  • LK Shields
  • Ireland
  • January 24 2013

Clinical trials play a pivotal role in the development of market-safe pharmaceuticals and medical devices and, needless to say, sit within an

News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The U.S. Food and Drug Administration (FDA) issues a final rule amending its "postmarketing safety reporting regulations for human drug and

News bytes - March 7, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • March 7 2013

The U.S. Patent and Trademark Office (USPTO) seeks public comments by May 3, 2013, on "information requirements related to civil actions and claims

Telehealth and health IT Policy: considerations for stakeholders
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 4 2014

In recent months, as the conversation about reforming the health care system has shifted to achieving greater delivery system efficiencies, cost

Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • May 5 2014

The amendments to the Patent Rules and Trade-marks Regulations affecting both patent and trade-mark agents came into effect on May 1, 2014. The